Foamix Pharmaceuticals Ltd (FOMX)
Sector • Consumer Non Cyclical Industry • Legal Cannabis |
Industry • Legal Cannabis |
Sector • Consumer Non Cyclical |
FOMX reported fourth quarter of 2019 operating surplus of $37.431 millions
Published Mar 25 2023
CSIMarket Team / CSIMarket.com
For the most recent fiscal period FOMX income per share grew by 7.89 % of $0.41 per share compare to $0.38 a year ago and EPS grew by 17.14 % from $0.35 per share from the prior reporting season.
Revenues remained unaffected to $0.00 millions from $0.87 millions in the corresponding reporting season a year ago and sequentially from $0.00 millions.
Net profits of $23.161 millions in the most recent fiscal period increased by 49.62 % from net earnings of $15.480 millions reported in the most recent fiscal period a year ago. Looking further into most recent fiscal period Foamix Pharmaceuticals Ltd 's profitability, operating margin mitigated to 0%, and net margin shrank to 0%.
Operating earnings, on the other hand, improved just 48.85% to $23.199 millions.
Revenues remained unaffected to $0.00 millions from $0.87 millions in the corresponding reporting season a year ago and sequentially from $0.00 millions.
Net profits of $23.161 millions in the most recent fiscal period increased by 49.62 % from net earnings of $15.480 millions reported in the most recent fiscal period a year ago. Looking further into most recent fiscal period Foamix Pharmaceuticals Ltd 's profitability, operating margin mitigated to 0%, and net margin shrank to 0%.
Operating earnings, on the other hand, improved just 48.85% to $23.199 millions.